RNA Dysregulation : An Expanding Source of Cancer Immunotherapy Targets
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved..
Cancer transcriptomes frequently exhibit RNA dysregulation. As the resulting aberrant transcripts may be translated into cancer-specific proteins, there is growing interest in exploiting RNA dysregulation as a source of tumor antigens (TAs) and thus novel immunotherapy targets. Recent advances in high-throughput technologies and rapid accumulation of multiomic cancer profiling data in public repositories have provided opportunities to systematically characterize RNA dysregulation in cancer and identify antigen targets for immunotherapy. However, given the complexity of cancer transcriptomes and proteomes, important conceptual and technological challenges exist. Here, we highlight the expanding repertoire of TAs arising from RNA dysregulation and introduce multiomic and big data strategies for identifying optimal immunotherapy targets. We discuss extant barriers for translating these targets into effective therapies as well as the implications for future research.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Trends in pharmacological sciences - 42(2021), 4 vom: 28. Apr., Seite 268-282 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pan, Yang [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 31.08.2021 Date Revised 05.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.tips.2021.01.006 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM322681081 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM322681081 | ||
| 003 | DE-627 | ||
| 005 | 20240405232113.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.tips.2021.01.006 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1366.xml |
| 035 | |a (DE-627)NLM322681081 | ||
| 035 | |a (NLM)33711255 | ||
| 035 | |a (PII)S0165-6147(21)00017-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pan, Yang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a RNA Dysregulation |b An Expanding Source of Cancer Immunotherapy Targets |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.08.2021 | ||
| 500 | |a Date Revised 05.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a Cancer transcriptomes frequently exhibit RNA dysregulation. As the resulting aberrant transcripts may be translated into cancer-specific proteins, there is growing interest in exploiting RNA dysregulation as a source of tumor antigens (TAs) and thus novel immunotherapy targets. Recent advances in high-throughput technologies and rapid accumulation of multiomic cancer profiling data in public repositories have provided opportunities to systematically characterize RNA dysregulation in cancer and identify antigen targets for immunotherapy. However, given the complexity of cancer transcriptomes and proteomes, important conceptual and technological challenges exist. Here, we highlight the expanding repertoire of TAs arising from RNA dysregulation and introduce multiomic and big data strategies for identifying optimal immunotherapy targets. We discuss extant barriers for translating these targets into effective therapies as well as the implications for future research | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a CAR-T | |
| 650 | 4 | |a RNA processing | |
| 650 | 4 | |a RNA-seq | |
| 650 | 4 | |a TCR | |
| 650 | 4 | |a cancer immunotherapy | |
| 650 | 4 | |a proteogenomics | |
| 650 | 4 | |a proteome | |
| 650 | 4 | |a transcriptome | |
| 650 | 4 | |a tumor antigen | |
| 650 | 7 | |a Proteome |2 NLM | |
| 650 | 7 | |a RNA |2 NLM | |
| 650 | 7 | |a 63231-63-0 |2 NLM | |
| 700 | 1 | |a Kadash-Edmondson, Kathryn E |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Phillips, John |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Song |e verfasserin |4 aut | |
| 700 | 1 | |a Ribas, Antoni |e verfasserin |4 aut | |
| 700 | 1 | |a Aplenc, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Witte, Owen N |e verfasserin |4 aut | |
| 700 | 1 | |a Xing, Yi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Trends in pharmacological sciences |d 1989 |g 42(2021), 4 vom: 28. Apr., Seite 268-282 |w (DE-627)NLM012599670 |x 1873-3735 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2021 |g number:4 |g day:28 |g month:04 |g pages:268-282 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.tips.2021.01.006 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2021 |e 4 |b 28 |c 04 |h 268-282 | ||